| HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients V Pannu, PCG Rida, A Ogden, RC Turaga, S Donthamsetty, NJ Bowen, ... Oncotarget 6 (8), 6076, 2015 | 126 | 2015 |
| The Noscapine Chronicle: A Pharmaco‐Historic Biography of the Opiate Alkaloid Family and its Clinical Applications PCG Rida, D LiVecche, A Ogden, J Zhou, R Aneja Medicinal research reviews 35 (5), 1072-1096, 2015 | 118 | 2015 |
| KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries S Pawar, S Donthamsetty, V Pannu, P Rida, A Ogden, N Bowen, R Osan, ... Journal of ovarian research 7 (1), 53, 2014 | 99 | 2014 |
| Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy A Ogden, PCG Rida, R Aneja Cell Death & Differentiation 19 (8), 1255-1267, 2012 | 96 | 2012 |
| Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration A Ogden, PCG Rida, R Aneja Cancer and Metastasis Reviews 32 (1-2), 269-287, 2013 | 84 | 2013 |
| Docetaxel-induced polyploidization may underlie chemoresistance and disease relapse A Ogden, PCG Rida, BS Knudsen, O Kucuk, R Aneja Cancer letters 367 (2), 89-92, 2015 | 76 | 2015 |
| Microtubule‐Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy S Xie, A Ogden, R Aneja, J Zhou Medicinal research reviews 36 (2), 300-312, 2016 | 60 | 2016 |
| Centrosome-declustering drugs mediate a two-pronged attack on interphase and mitosis in supercentrosomal cancer cells V Pannu, PCG Rida, B Celik, RC Turaga, A Ogden, G Cantuaria, ... Cell death & disease 5 (11), e1538, 2014 | 53 | 2014 |
| Interphase microtubules: chief casualties in the war on cancer? A Ogden, PCG Rida, MD Reid, R Aneja Drug discovery today 19 (7), 824-829, 2014 | 50 | 2014 |
| Prognostic value of CA20, a score based on centrosome amplification-associated genes, in breast tumors A Ogden, PCG Rida, R Aneja Scientific Reports 7, 2017 | 42 | 2017 |
| Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: a novel chemotherapeutic approach V Pannu, PCG Rida, A Ogden, R Clewley, A Cheng, P Karna, M Lopus, ... Cell death & disease 3 (7), e346, 2012 | 38 | 2012 |
| Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer A Ogden, C Garlapati, XB Li, RC Turaga, G Oprea-Ilies, N Wright, ... Scientific Reports 7, 42289, 2017 | 36 | 2017 |
| Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death A Ogden, A Cheng, PCG Rida, V Pannu, R Osan, R Clewley, R Aneja Cell death & disease 5 (5), e1204, 2014 | 32 | 2014 |
| Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma K Mittal, A Ogden, MD Reid, PCG Rida, S Varambally, R Aneja Cell Cycle 14 (17), 2798-2809, 2015 | 28 | 2015 |
| Mitochondrial genome regulates mitotic fidelity by maintaining centrosomal homeostasis S Donthamsetty, M Brahmbhatt, V Pannu, P Rida, S Ramarathinam, ... Cell Cycle 13 (13), 2056-2255, 2014 | 24 | 2014 |
| Centrosome amplification: a suspect in breast cancer and racial disparities A Ogden, PCG Rida, R Aneja Endocrine-Related Cancer, ERC-17-0072, 2017 | 22 | 2017 |
| Diverse roles of HDAC6 in viral infection: Implications for antiviral therapy L Zhang, A Ogden, R Aneja, J Zhou Pharmacology & therapeutics 164, 120-125, 2016 | 22 | 2016 |
| Die-hard survivors: heterogeneity in apoptotic thresholds may underlie chemoresistance A Ogden, PCG Rida, MD Reid, O Kucuk, R Aneja Expert review of anticancer therapy 15 (3), 277-281, 2015 | 11 | 2015 |
| Nuclear HSET, a predictor for metastasis, disease relapse, and poor survival, is a racial disparity biomarker in triple-negative breast cancer patients A Ogden, G Oprea-Ilies, PCG Rida, D Nickleach, Y Liu, G Cantuaria, ... CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 23 (11), 2014 | 1 | 2014 |
| A combined HER3-EGFR score in triple-negative breast cancer: racial differences. A Ogden, S Bhattarai, N Wright, S Klimov, S Pattni, M Aleskandarany, ... Journal of Clinical Oncology 34 (15_suppl), e12560-e12560, 2016 | | 2016 |
